  Background: In this second part of a two-part paper, we intend to demonstrate
the impact of the previously proposed advanced quality control pipeline. To
understand its benefit and challenge the proposed methodology in a real
scenario, we chose to compare the outcome when applying it to the analysis of
two patient populations with a significant but highly different types of
fatigue: COVID19 and multiple sclerosis (MS). Experimental: 31P-MRS was
performed on a 3T clinical MRI, in 19 COVID19 patients, 38 MS patients, and 40
matched healthy controls. Dynamic acquisitions using an MR-compatible ergometer
ran over a rest(40s), exercise(2min), and a recovery phase(6min). Long and
short TR acquisitions were also made at rest for T1 correction. The advanced
data quality control pipeline presented in part 1 is applied to the selected
patient cohorts to investigate its impact on clinical outcomes. We first used
power and sample size analysis to estimate objectively the impact of adding
QCS. Then, comparisons between patients and healthy control groups using
validated QCS were performed using unpaired T-tests or Mann-Whitney tests
(p<0.05).Results: The application of the QCS resulted in increased statistical
power, changed the values of several outcome measures, and reduced variability
(SD). A significant difference was found between the T1PCr and T1Pi of MS
patients and healthy controls. Furthermore, the use of a fixed correction
factor led to systematically higher estimated concentrations of PCr and Pi than
when using individually corrected factors. We observed significant differences
between the two patient populations and healthy controls for resting [PCr] --
MS only, [Pi], [ADP], [H2PO4-] and pH -- COVID19 only, and post-exercise
[PCr],[Pi] and [H2PO4-] - MS only. The dynamic indicators $\tau$PCr, $\tau$Pi,
ViPCr and Vmax were reduced for COVID19 and MS patients compared to controls.
Conclusion: Our results show that QCS in dynamic 31P-MRS studies results in
smaller data variability and therefore impacts study sample size and power.
Although QCS resulted in discarded data and therefore reduced the acceptable
data and subject numbers, this rigorous and unbiased approach allowed for
proper assessment of muscle metabolites and metabolism in patient populations.
The outcomes include an increased metabolite T1, which directly affect the T1
correction factor applied to the amplitudes of the metabolite, and a prolonged
$\tau$PCr indicating reduced muscle oxidative capacity for patients with MS and
COVID19.
